» Articles » PMID: 11231351

Expression of Osteopontin in Gentamicin-induced Acute Tubular Necrosis and Its Recovery Process

Overview
Journal Kidney Int
Publisher Elsevier
Specialty Nephrology
Date 2001 Mar 7
PMID 11231351
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Background: There is controversy regarding the exact localization and roles of osteopontin (OPN), a multipotential chemokine, in renal injury. There is little information on the expression and role of OPN in gentamicin-induced acute tubular necrosis (ATN) and its recovery process.

Methods: A severe ATN model was made using male Wistar rats by injecting gentamicin (150 mg/kg/day) for five days and limiting the provision of water. The expression and localization of OPN mRNA and protein, ED1 as a macrophage marker, proliferating cellular nuclear antigen (PCNA), CD44 as an OPN receptor, megalin as a proximal tubule marker, and their relationships to each other were examined from the early tubular necrotic period to the late recovery period by Northern blotting, in situ hybridization, and double immunohistochemical staining.

Results: In the gentamicin group, OPN mRNA and protein were expressed in only the PCNA-positive proliferating cortical distal tubules, not in the necrotic proximal tubules, until day 6 after the first administration, but were found markedly in PCNA-positive regenerative proximal and distal tubules on days 10, 15, and 30. The localization of PCNA-positive cells was almost always accompanied with the up-regulated expression of OPN using quantitative analysis (P < 0.01). CD44 expression was markedly up-regulated in the renal cortical tubular epithelium from days 6 to 30. In the control group, no expression of OPN and CD44 in the cortical area was found throughout the experimental period.

Conclusions: These results suggested that OPN is related to the proliferation and regeneration of tubular epithelial cells after tubular damage.

Citing Articles

Proteomic Changes Induced by the Immunosuppressant Everolimus in Human Podocytes.

Bruschi M, Granata S, Candiano G, Petretto A, Bartolucci M, Kajana X Int J Mol Sci. 2024; 25(13).

PMID: 39000447 PMC: 11242170. DOI: 10.3390/ijms25137336.


Rosuvastatin as a Supplemental Treatment for the Clinical Symptoms of Nephropathia Epidemica: A Pilot Clinical Study.

Shakirova V, Markelova M, Davidyuk Y, Stott-Marshall R, Foster T, Khaiboullina S Viruses. 2024; 16(2).

PMID: 38400081 PMC: 10892398. DOI: 10.3390/v16020306.


Assessment of Amikacin- and Capreomycin-Related Adverse Drug Reactions in Patients with Multidrug-Resistant Tuberculosis and Exploring the Role of Genetic Factors.

Freimane L, Barkane L, Kivrane A, Sadovska D, Ulanova V, Ranka R J Pers Med. 2023; 13(4).

PMID: 37108985 PMC: 10145258. DOI: 10.3390/jpm13040599.


StemPanTox: A fast and wide-target drug assessment system for tailor-made safety evaluations using personalized iPS cells.

Yamane J, Wada T, Otsuki H, Inomata K, Suzuki M, Hisaki T iScience. 2022; 25(7):104538.

PMID: 35754715 PMC: 9218511. DOI: 10.1016/j.isci.2022.104538.


Cisplatin nephrotoxicity in male beagle dogs: next-generation protein kidney safety biomarker tissue expression and related changes in urine.

McDuffie J, Chen Y, Ma J, Lee S, Lynch K, Hamlin D Toxicol Res (Camb). 2018; 5(4):1202-1215.

PMID: 30090426 PMC: 6062370. DOI: 10.1039/c5tx00497g.